Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin- converting enzyme inhibitor

Japanese Circulation Journal

Volumn 64, Issue 5, 2000, Pages 365-369

  Hara, Yuji ^a   Hamada, Mareomi ^a   Shigematsu, Yuji ^a   Suzuki, Makoto ^a   Kodama, Koji ^a   Kuwahara, Taishi ^a   Hashida, Hidetoshi ^a   Ikeda, Shuntaro ^a   Ohtsuka, Tomoaki ^a   Hiasa, Go ^a   Hiwada, Kunio ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Beta blocker; Heart failure; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; METOPROLOL; NATRIURETIC FACTOR; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; DIGITALIS; DIURETICS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; METOPROLOL; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHYTOTHERAPY; PLANTS, MEDICINAL; PLANTS, TOXIC; VENTRICULAR FUNCTION, LEFT;

EID: 0347243570     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.64.365     Document Type: Article

References (30)

1. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
2. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
3. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al for the Metprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441 - 1446
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355
5. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines Committee on evaluation and management of heart failure. Circulation 1995; 92: 2764-2784
6. Doughty RN, Rodgers A, Sharpe N, MacMahon S: Effects of beta-blocker therapy on mortality in patients with heart failure: A systematic overview of randomized controlled trials. Eur Heart J 1997; 18: 560-565
7. Lechat P, Packer M, Cholon S, Cucheral M, Arab T, Boissel JP: Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-1191
8. Hofmann T, Meinertz T, Kasper W, Geibel A, Zehender M, Hohnloser S, et al: Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. Am Heart J 1988; 116: 1455-1463
9. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ: Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy: Relation to symptoms and prognosis. Circulation 1994; 90: 2772-2779
10. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F and the Heart Muscle Disease Study Group: Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol 1993; 22: 808-815
11. Hara Y, Hamada M, Hiwada K: Left ventricular end-systolic wall stress is a potent prognostic variable in patients with dilated cardiomyopathy. Jpn Circ J 1999; 63: 196-200
12. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, et al: Atria natriuretic peptide elevation in congestive heart failure in the humans. Science 1986; 231: 1145-1147
13. Cody RJ, Atlas SA. Laraph JH, Kubo SH, Covit AB, Ryman KS, et al: Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362-1374
14. Raine AEG, Erne P, Bürgisser E, Müller FB, Bolli P, Burkart F, et al: Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986; 315: 533-537
15. Yoshimura M, Yasue H, Okumura K. Ogawa H, Jougasaki M, Mukoyama M, et al: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-469
16. Davidson NC, Coutie WJ, Webb DJ, Struthers AD: Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 1996; 75: 576-581
17. Rahman MA, Hara K. Daly PA, Wigle ED, Floras JS: Reductions in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy: preliminary observations. Br Heart J 1995; 74: 431-436
18. Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akaishi M, et al: Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure. Am Heart J 1996; 131:329-336
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A: The Committee on M-mode Standardization of The American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
20. Hamada M, Shigematsu Y, Kawakami H, Minamino N. Kangawa K, Matsuo H, et al: Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-1, natriuretic peptides and noradrenaline. Clin Sci 1998; 94: 21-28
21. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Pass SM, Grayburn PA, et al: Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310-1320
22. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, et al: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol 1994; 23: 943-950
23. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-1231
24. Staessen J. Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma concentration of aldosterone during long-term angiotensin-II suppression. J Endocrinol 1981; 91: 457-465
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al for the Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
26. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92: 1499-1506
27. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin-II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890
28. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, et al: Cellular localization and regional distribution of an angiotensin-II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281
29. Bates ER, Shenker Y, Grekin RJ: The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodymanic function in man. Circulation 1986; 73: 1155-1161
30. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516